Skip to main content

Peer Review reports

From: Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

Original Submission
27 Feb 2018 Submitted Original manuscript
26 Mar 2018 Author responded Author comments - Zongbi Yi
Resubmission - Version 2
26 Mar 2018 Submitted Manuscript version 2
23 Jul 2018 Reviewed Reviewer Report - Hans J Neubauer
13 Sep 2018 Reviewed Reviewer Report - Anthony D. Elias
13 Oct 2018 Author responded Author comments - Zongbi Yi
Resubmission - Version 3
13 Oct 2018 Submitted Manuscript version 3
12 Apr 2019 Reviewed Reviewer Report - Reviewer 2
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
1 May 2019 Editorially accepted
14 May 2019 Article published 10.1186/s12885-019-5668-3

You can find further information about peer review here.

Back to article page